A detailed history of Man Group PLC transactions in Veracyte, Inc. stock. As of the latest transaction made, Man Group PLC holds 415,774 shares of VCYT stock, worth $15.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
415,774
Previous 679,298 38.79%
Holding current value
$15.4 Million
Previous $14.7 Million 3.89%
% of portfolio
0.04%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$21.0 - $35.25 $5.53 Million - $9.29 Million
-263,524 Reduced 38.79%
415,774 $14.1 Million
Q2 2024

Aug 14, 2024

BUY
$18.86 - $23.55 $3.94 Million - $4.91 Million
208,650 Added 44.33%
679,298 $14.7 Million
Q1 2024

May 15, 2024

BUY
$21.0 - $29.1 $812,826 - $1.13 Million
38,706 Added 8.96%
470,648 $10.4 Million
Q4 2023

Feb 14, 2024

BUY
$19.72 - $28.68 $4.18 Million - $6.08 Million
211,889 Added 96.29%
431,942 $11.9 Million
Q3 2023

Nov 14, 2023

BUY
$22.33 - $29.92 $3.56 Million - $4.77 Million
159,431 Added 262.99%
220,053 $4.91 Million
Q2 2023

Aug 14, 2023

BUY
$20.96 - $26.99 $1.27 Million - $1.64 Million
60,622 New
60,622 $1.54 Million
Q3 2022

Nov 14, 2022

SELL
$16.58 - $27.9 $137,630 - $231,597
-8,301 Reduced 19.02%
35,334 $587,000
Q2 2022

Aug 15, 2022

SELL
$15.45 - $29.52 $1.99 Million - $3.8 Million
-128,774 Reduced 74.69%
43,635 $869,000
Q1 2022

May 16, 2022

BUY
$21.94 - $42.51 $3.78 Million - $7.33 Million
172,409 New
172,409 $4.75 Million
Q3 2021

Nov 15, 2021

SELL
$35.62 - $52.97 $423,877 - $630,343
-11,900 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$32.94 - $56.62 $98,820 - $169,860
3,000 Added 33.71%
11,900 $476,000
Q1 2021

May 17, 2021

SELL
$44.47 - $81.38 $65,548 - $119,954
-1,474 Reduced 14.21%
8,900 $478,000
Q4 2020

Feb 16, 2021

BUY
$32.49 - $61.88 $337,051 - $641,943
10,374 New
10,374 $508,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.65B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.